101: A Single Institution Retrospective Study of Pelvic Insufficiency Fractures Following Curative-Intent Pelvic Intensity-Modulated Radiation Therapy for Gynecologic, Gastrointestinal and Genitourinary Cancers

2021 ◽  
Vol 163 ◽  
pp. S44
Author(s):  
Said Al Saifi ◽  
Marc Gaudet ◽  
Scott Morgan ◽  
Alain Haddad ◽  
Krystine Lupe ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Retrospective Study ◽  
Intensity Modulated Radiation Therapy ◽  
Insufficiency Fractures ◽  
Single Institution ◽  
Curative Intent ◽  
Intensity Modulated ◽  
Genitourinary Cancers

scholarly journals Cisplatin plus capecitabine concomitant with intensity-modulated radiation therapy in non-metastatic anal squamous cell carcinoma: the experience of a single research cancer center

2020 ◽  
Vol 12 ◽  
pp. 175883592094094 ◽  
Author(s):  
Maria Saveria Rotundo ◽  
Maria Giulia Zampino ◽  
Paola Simona Ravenda ◽  
Vincenzo Bagnardi ◽  
Giulia Peveri ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Radiation Therapy ◽  
Retrospective Study ◽  
Cell Carcinoma ◽  
Survival Rates ◽  
Intensity Modulated Radiation Therapy ◽  
Curative Intent ◽  
Anal Squamous Cell Carcinoma ◽  
Free Survival ◽  
Intensity Modulated

Background and Aims: The standard treatment of non-metastatic anal squamous cell carcinoma (ASCC) consists of chemotherapy with mitomycin (MMC) plus 5-fluorouracil (5FU) for 1–2 cycles concomitant with pelvic radiotherapy. Subsequent studies introduced cisplatin (CDDP) combined with 5FU, with unclear results. We evaluated the doublet capecitabine (C) and CDDP as a possible alternative to MMC-5FU regimen concomitant with intensity-modulated radiation therapy (IMRT). Patients and Methods: We carried out a retrospective study on 67 patients affected by stage I–III ASCC, treated with CDDP (60–70 mg/m2 every 21 days for two courses) plus C (825 mg/m2 twice daily for 5 days/week) chemotherapy concomitant with IMRT for curative intent. Results: At a median follow up of 41 months, the clinical complete response calculated at the 6-month time-point (6-moCR), the 6-month objective response rate and the 6-month disease control rate were 93%, 94%, and 99%, respectively. Disease-free survival rates at 1, 2, and 3 years were 89%, 87%, and 85%, while the overall survival rates at 1 and 2 years were 100% and 95%. The colostomy-free survival rates were 90% at 1 year and 88% at 2 years. Grade 3–4 acute adverse events were reported in 61% of patients; predominantly skin toxicity (46%) and limited hematological toxicity (12%). Conclusion: In this retrospective study, chemotherapy with C plus CDDP concomitant with IMRT proved safe and effective, and may represent a possible alternative option to standard MMC-containing regimen for curative intent.

Sign in / Sign up

Export Citation Format

Share Document